CIDCA 133通过调节上皮屏障和TLR2/4/Myd88/NF-κB信号通路改善化疗引起的粘膜炎。

CIDCA 133 Ameliorates Chemotherapy-Induced Mucositis by Modulating Epithelial Barrier and TLR2/4/Myd88/NF-κB Signaling Pathway.

作者信息

Barroso Fernanda Alvarenga Lima, de Jesus Luís Cláudio Lima, da Silva Tales Fernando, Batista Viviane Lima, Laguna Juliana, Coelho-Rocha Nina Dias, Vital Kátia Duarte, Fernandes Simone Odília Antunes, Cardoso Valbert Nascimento, Ferreira Enio, Martins Flaviano Santos, Drumond Mariana Martins, Mancha-Agresti Pamela, Birbrair Alexander, Barh Debmalya, Azevedo Vasco

机构信息

Departamento de Genética, Ecologia e Evolução, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.

Departamento de Análises Clínicas e Toxicológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.

出版信息

Front Microbiol. 2022 Apr 26;13:858036. doi: 10.3389/fmicb.2022.858036. eCollection 2022.

Intestinal mucositis promoted by the use of anticancer drugs is characterized by ulcerative inflammation of the intestinal mucosa, a debilitating side effect in cancer patients undergoing treatment. Probiotics are a potential therapeutic option to alleviate intestinal mucositis due to their effects on epithelial barrier integrity and anti-inflammatory modulation. This study investigated the health-promoting impact of CIDCA 133 in modulating inflammatory and epithelial barrier markers to protect the intestinal mucosa from 5-fluorouracil-induced epithelial damage. CIDCA 133 consumption ameliorated small intestine shortening, inflammatory cell infiltration, intestinal permeability, villus atrophy, and goblet cell count, improving the intestinal mucosa architecture and its function in treated mice. Upregulation of , , , , and , and downregulation of markers involved in NF-κB signaling pathway activation (, and ) were observed at the mRNA level. This work suggests a beneficial role of strain CIDCA 133 on intestinal damage induced by 5-FU chemotherapy through modulation of inflammatory pathways and improvement of epithelial barrier function.

使用抗癌药物引发的肠道黏膜炎的特征是肠道黏膜出现溃疡性炎症，这是癌症治疗患者中一种使人虚弱的副作用。益生菌因其对上皮屏障完整性的影响和抗炎调节作用，是缓解肠道黏膜炎的一种潜在治疗选择。本研究调查了CIDCA 133在调节炎症和上皮屏障标志物以保护肠道黏膜免受5-氟尿嘧啶诱导的上皮损伤方面对健康的促进作用。食用CIDCA 133改善了小肠缩短、炎症细胞浸润、肠道通透性、绒毛萎缩和杯状细胞计数，改善了治疗小鼠的肠道黏膜结构及其功能。在mRNA水平上观察到、、、和的上调，以及参与NF-κB信号通路激活的标志物（、和）的下调。这项工作表明CIDCA 133菌株通过调节炎症途径和改善上皮屏障功能，对5-氟尿嘧啶化疗诱导的肠道损伤具有有益作用。